We report potent in vitro CD137-mediated activation only upon engagement of PD-L1 using the anti-CD137/PD-L1 bispecific mAb2 which outperforms monospecific antibodies on their own and in combination in multiple syngeneic mouse tumour models in a dose-dependent manner. Here, TNFRSF9 is linked to neoplasm.